What question did this study set out to answer?

The aim is to compare the pharmacokinetic profiles of ultrarapid lispro (Lyumjev) and Humalog in adults with type 1 diabetes during exercise.

March 28, 2026

Ultrarapid Lispro (Lyumjev) Has an Improved Pharmacokinetic Profile for Exercise Compared With Humalog, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion

Key Points

The aim is to compare the pharmacokinetic profiles of ultrarapid lispro (Lyumjev) and Humalog in adults with type 1 diabetes during exercise.
Conducted under open-loop continuous subcutaneous insulin infusion (CSII) therapy
Compared bolus rate reductions (BRRs) before exercise
Assessed hypoglycemic events during physical activity
Lyumjev showed more effective BRRs prior to exercise than Humalog
Fewer hypoglycemic events occurred with Lyumjev compared to Humalog
Hypoglycemic events were significantly reduced in active adults

Abstract

Using Lyumjev in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with Humalog, with fewer hypoglycemic events in active adults with type 1 diabetes.

AI에게 질문

Bookmark